🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Chidamide

Also listed in trial records as HBI-8000, HDACi, CS055
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 47 trials in our China, UK and USA registers that name Chidamide as an intervention. Synced 25 Sep 2026
47Trials tracked
37Recruiting now
25Lead sponsors
3Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

Chidamide is named as a drug or biological intervention in 47 clinical trials in our China, UK and USA trial registers, 37 of which are recruiting. Lead sponsors include Tianjin Medical University Cancer Institute and Hospital (6), Chinese PLA General Hospital (5) and The First Affiliated Hospital of Soochow University (4). Registered phases: Phase 2, Phase 1/2, Phase 3, Not applicable and Phase 1. Conditions studied include Peripheral T Cell Lymphoma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma (DLBCL).

01

Clinical trials of Chidamide

47 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT07493109 Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma (DLBCL)
 Phase 3 Recruiting Ou Bai, MD/PHD China
NCT07514936 Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (ClinicalTrials.gov ↗)
Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
 Phase 3 Recruiting Chinese PLA General Hospital China
NCT05088226 Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen (ClinicalTrials.gov ↗)
Peripheral Blood Stem Cell Transplantation
 Phase 2 Recruiting Chinese PLA General Hospital China
NCT05348213 Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B Cell Lymphoma
 Phase 2 Recruiting Ruijin Hospital China
NCT05566054 Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia (ClinicalTrials.gov ↗)
Acute Monocytic Leukemia, Newly Diagnosed
 Phase 2 Recruiting The First Affiliated Hospital of Soochow University China
NCT05958719 Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Peripheral T Cell Lymphoma, Epigenetic Repression
 Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT05983107 Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (ClinicalTrials.gov ↗)
HR+/HER2- Advanced Breast Cancer, Targeted Therapy
 Phase 2 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
NCT06158386 Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
 Phase 2 Recruiting The First Affiliated Hospital of Xiamen University China
NCT06220162 VAC Regimen for AML Patients Who Failed to Response to VA Regimen (ClinicalTrials.gov ↗)
Acute Myeloid Leukemia
 Phase 2 Recruiting The First Affiliated Hospital of Soochow University China
NCT06393361 Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (ClinicalTrials.gov ↗)
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
 Phase 2 Recruiting Chinese PLA General Hospital China
NCT06451861 Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML (ClinicalTrials.gov ↗)
Acute Myeloid Leukemia
 Phase 2 Recruiting Guangdong Provincial People's Hospital China
NCT06570447 Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT06685276 Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer (ClinicalTrials.gov ↗)
Colorectal Cancer Metastatic
 Phase 2 Recruiting Dai, Guanghai China
NCT06739395 Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (ClinicalTrials.gov ↗)
Solid Tumor, Precision Medicine
 Phase 2 Recruiting Tianjin Medical University Second Hospital China
NCT06758037 Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy (ClinicalTrials.gov ↗)
DLBCL, Diffuse Large B-Cell Lymphoma
 Phase 2 Recruiting First Affiliated Hospital of Ningbo University China
NCT06891157 Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes (ClinicalTrials.gov ↗)
Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma
 Phase 2 Recruiting The First Affiliated Hospital with Nanjing Medical University China
NCT06928376 A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (ClinicalTrials.gov ↗)
Acute Myeloid Leukemia, First Line Therapy
 Phase 2 Recruiting Chinese PLA General Hospital China
NCT06951997 QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗)
Metastatic Pancreatic Cancer
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT06979908 A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer (ClinicalTrials.gov ↗)
Metastatic Colorectal Cancer
 Phase 2 Recruiting The First Hospital of Jilin University China
NCT07159620 Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients (ClinicalTrials.gov ↗)
Adult T-cell Leukemia/Lymphoma
 Phase 2 Recruiting The First Affiliated Hospital of Soochow University China
NCT07304232 Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML (ClinicalTrials.gov ↗)
Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
 Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT07318831 Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children (ClinicalTrials.gov ↗)
Neuroblastoma (NB), Neuroblastoma in Children
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT07380984 PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (ClinicalTrials.gov ↗)
Natural Killer/T-cell Lymphoma
 Phase 2 Recruiting Ruijin Hospital China
NCT07397832 CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma (DLBCL)
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT07412262 A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 2 Recruiting Guangdong Association of Clinical Trials China
NCT07493148 Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma (DLBCL)
 Phase 2 Recruiting Ou Bai, MD/PHD China
NCT07507318 Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 2 Recruiting Rong Tao China
NCT07518602 Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma (ClinicalTrials.gov ↗)
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
 Phase 2 Recruiting Sun Yat-sen University China
NCT04025450 Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1/2 Recruiting The First Affiliated Hospital of Soochow University China
NCT05270200 Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse (ClinicalTrials.gov ↗)
Leukemia, Myeloid, Acute
 Phase 1/2 Recruiting Zhujiang Hospital China
NCT05675813 Genotype-guided Treatment in Newly Diagnosed PTCL (ClinicalTrials.gov ↗)
Peripheral T Cell Lymphoma
 Phase 1/2 Recruiting Ruijin Hospital China
NCT05682755 Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT (ClinicalTrials.gov ↗)
Leukemia, Myeloid, Acute
 Phase 1/2 Recruiting Sichuan University China
NCT07093710 Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (ClinicalTrials.gov ↗)
Peripheral T Cell Lymphoma
 Phase 1/2 Recruiting Sun Yat-sen University China
NCT07754890 Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma (ClinicalTrials.gov ↗)
Cutaneous T-cell Lymphoma (CTCL)
 Phase 1/2 Recruiting Peking Union Medical College Hospital China
NCT07545967 Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy (ClinicalTrials.gov ↗)
Head and Neck Squamous Cell Carcinoma HNSCC
 Phase 1 Recruiting West China Hospital China
NCT05890287 A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy (ClinicalTrials.gov ↗)
HR Positive HER2 Negative Advanced Breast Cancer
 Not applicable Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT06386302 Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (ClinicalTrials.gov ↗)
AML, Acute Myeloid Leukemia
 Not applicable Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT06556862 Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor (ClinicalTrials.gov ↗)
HR+/HER2- Advanced Breast Cancer
 Phase 2 Not yet open Beijing 302 Hospital China
NCT06563778 Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (ClinicalTrials.gov ↗)
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
 Phase 2 Not yet open Chinese PLA General Hospital China
NCT07616336 Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes (ClinicalTrials.gov ↗)
Myelodysplastic Syndromes
 Phase 2 Not yet open Zhongshan Hospital (Xiamen), Fudan University China
NCT07746245 The Efficacy of CAPCT in Patients With PTCL (ClinicalTrials.gov ↗)
Peripheral T-Cell Lymphoma
 Phase 2 Not yet open The First Affiliated Hospital with Nanjing Medical University China
NCT07601607 Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
 Phase 1/2 Not yet open Sun Yat-sen University China
NCT05678933 AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH (ClinicalTrials.gov ↗)
Peripheral T-cell Lymphoma Targeted Therapy
 Phase 3 By invitation Tianjin Medical University Cancer Institute and Hospital China
NCT04668690 Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL (ClinicalTrials.gov ↗)
Peripheral T Cell Lymphoma
 Phase 3 Active, closed CSPC ZhongQi Pharmaceutical Technology Co., Ltd. China
NCT04674683 Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma (ClinicalTrials.gov ↗)
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
 Phase 3 Active, closed HUYABIO International, LLC. UK, USA
NCT04562311 Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ClinicalTrials.gov ↗)
Bladder Cancer Stage IV
 Phase 2 Active, closed Sun Yat-sen University China
NCT06550336 A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). (ClinicalTrials.gov ↗)
Peripheral T Cell Lymphoma
 Phase 2 Active, closed The First Hospital of Jilin University China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

51 conditions
Condition (as registered)Trials
Peripheral T Cell Lymphoma5
Acute Myeloid Leukemia4
Diffuse Large B-Cell Lymphoma (DLBCL)3
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma2
Leukemia, Myeloid, Acute2
Diffuse Large B-Cell Lymphoma2
HR+/HER2- Advanced Breast Cancer2
Unresectable or Metastatic Melanoma1
Progressive Brain Metastasis1
Epigenetic Repression1
Natural Killer/T-cell Lymphoma1
First Line Therapy1
Colorectal Cancer Metastatic1
Peripheral T-cell Lymphoma Targeted Therapy1
Neuroblastoma (NB)1
Neuroblastoma in Children1
Metastatic Pancreatic Cancer1
Metastatic Colorectal Cancer1
Allogeneic Hematopoietic Cell Transplantation (HCT)1
AML (Acute Myeloid Leukemia)1
Head and Neck Squamous Cell Carcinoma HNSCC1
Adult T-cell Leukemia/Lymphoma1
Multiple Myeloma1
Solid Tumor1
Precision Medicine1
DLBCL1
Diffuse Large B Cell Lymphoma1
Targeted Therapy1
HR Positive HER2 Negative Advanced Breast Cancer1
Non-Small Cell Lung Cancer1
AML1
Acute Monocytic Leukemia1
Newly Diagnosed1
Myelodysplastic Syndromes1
Peripheral T-Cell Lymphoma1
Diffuse Large B-Cell Lymphoma-Recurrent1
Diffuse Large B-Cell Lymphoma-Refractory1
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)1
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)1
Follicular Lymphoma1

+ 11 more conditions in the trial records above.

03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Tianjin Medical University Cancer Institute and Hospital6
Chinese PLA General Hospital5
The First Affiliated Hospital of Soochow University4
Sun Yat-sen University4
Institute of Hematology & Blood Diseases Hospital, China3
Ruijin Hospital3
Ou Bai, MD/PHD2
The First Hospital of Jilin University2
The First Affiliated Hospital with Nanjing Medical University2
HUYABIO International, LLC.1
Dai, Guanghai1
Zhujiang Hospital1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1
West China Hospital1
Tianjin Medical University Second Hospital1
Sichuan University1
First Affiliated Hospital of Ningbo University1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Guangdong Association of Clinical Trials1
Beijing 302 Hospital1
Guangdong Provincial People's Hospital1
Zhongshan Hospital (Xiamen), Fudan University1
The First Affiliated Hospital of Xiamen University1
Rong Tao1
Peking Union Medical College Hospital1
04

Trials by country register

RegisterChidamide trials
Clinical trials in China46
Clinical trials in UK1
Clinical trials in USA1

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Chidamide works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Chidamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.